Cellular metabolic activity as a marker of cytotoxicity and immunotropicity of probiotics’ derivatives
Abstract
Structural components of cells and metabolites of probiotics with biologically active potential, along with the study of effectiveness, require a series of tests to ensure their safety. The study aims to test the cytotoxicity and potential of structural and metabolic derivatives of Bifidobacterium bifidum and Lactobacillus reuteri to affect the immunocompetent cells using in vitro tests that characterize the metabolic activity of test-cells. Structural components of probiotic bacteria were obtained by the physical method of disintegration – cyclic freezing-thawing. Metabolic derivatives were obtained by cultivation of producers – bifidobacteria and lactobacilli in their own disintegrates. Cultures of mouse embryonic fibroblasts and splenocytes were used as the test cells. MTT and Alamar Blue® were used as redox indicators. According to the MTT test, filtrates that contain structural and metabolic derivates at a concentration of 5% and 10% in the incubation medium did not cause significant changes in the metabolic activity of the embryonic mouse fibroblasts. An increase of up to 20% of content in the incubation medium of filtrates of lactobacilli disintegrates led to a reduction of metabolic activity of test cells by 52.7 ± 6.2%, of filtrates of bifidobacteria disintegrates – by 26.5 ± 6.5%, of filtrates of lactobacterium culture – by 15.7 ± 6.9%, of filtrates of bifidobacterium cultures - by 40.4 ± 6.8%. According to the Alamar Blue® test, filtrates that contained only structural derivatives of lactobacilli and bifidobacteria at concentrations of 5% and 10%, as well as filtrates that contained a complex of structural and metabolic derivatives at a concentration of 5%, did not cause significant changes in the reducing ability of mouse splenocytes. At concentrations of 10%, filtrate containing a complex of structural and metabolic derivatives of lactobacilli, caused the inhibition of metabolic activity of splenocytes by 14.6 ± 3.5%, and bifidobacteria – by 10.0 ± 2.8%. With the contents of the incubation medium at 20% concentration, the filtrate of the disintegrates of lactobacilli decreased the metabolic activity of splenocytes by 12.2 ± 3.0%, and the filtrate of lactobacillus cultures that were grown on their own disintegrates – by 43.2 ± 3.3%. Increasing the content of the disintegrate filtrate and the bifidobacteria culture that were grown on their own disintegrates in the culture medium by up to 20% led to a decrease the metabolic activity of splenocytes by 38.0 ± 2.0%. Thus, the research has shown: the orientation of changes in cellular metabolism under the influence of the studied biologically active derivatives is similar in all model systems, and their intensity depends on the type of test cells, regenerative substrates and concentration of the agent of influence in model systems. The obtained results stimulate further exploration of the immunotropicity of the investigated derivatives of probiotic bacteria and can be used for development of new immunobiological preparations.References
Bauer, J. A., Salvagni, M., Vigroux, J. P. L., Chalvet, L. L. G., & Chiavaroli, C. (2010). Immunomodulatory extracts from Lactobacillus bacteria and me thods of manufacturing and use thereof. U.S. Patent No 20100055082A1. U.S. Patent and Trademark Office, Washington.
Habriev, R. U. (2005). Rukovodstvo po eksperimental'nomu (doklinicheskomu) izucheniju novyh farmakologicheskih veshhestv [Manual on experimental (preclinical) study of new pharmacological substances]. Medicina, Moscow (in Russian).
Kang, H. J., & Connolly, E. (2016). Method of improving immune function in mammals using lactobacillus strains with certain lipids. U.S. Patent No 2016/0287702 A1. U.S. Patent and Trademark Office, Washington.
Knysh, O. V., Isajenko, O. J., Babych, J. M., Poljans'ka, V. P., Zachepylo, S. V., Kompanijec', A. M., & Gorbach, T. V. (2018). Sposib oderzhannja biolo gichno aktyvnyh deryvativ bakterij probiotychnyh shtamiv [Method for ob taining biologically active derivatives of bacteria of probiotic strains]. Patent of Ukraine for useful model No 122859. Derzhavne Patentne Vidomstvo Ukrainy, Kyiv (in Ukrainian).
Kozlov, I. G., & Andronova, T. M. (2013). Lekarstvennyye vozdeystviya cherez retseptory vrozhdennogo immuniteta [Effect of medicines via innate immu nity receptors]. Allergologiya i Immunologiya, 14(4), 254–259 (in Russian).
Riss, T. L., Moravec R. A., Niles, A. L., Benink, H. A., Worzella, T. J., & Minor, L. (2016). Cell viability assays. In: Sittampalam, G. S., Coussens, N. P., Nelson, H., Arkin, M., Auld, D., Austin, C. et al. (Eds.). Assay guidance manual. Eli Lilly & Company, Bethesda.
Shafran, L. M., Mokienko, A. V., Petrenko, N. F., Gozhenko, A. I., & Nasibullin, B. A. (2010). K obosnovaniyu gormezisa kak fundamentalnoy biomeditsin skoy paradigmy [On the substantiation of hormesis as fundamental biome dical paradigm]. Sovremennye Problemy Toksikologii, 49–50(2–3), 13–23 (in Russian).
Stefanov, О. V. (2001). Doklinichni doslidzhennia likars'kyh zasobiv [Preclinical studies of drugs]. Avicena, Kyiv (in Ukrainian).
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons «Attribution» 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.